Skip to main content
Top
Published in: Surgery Today 5/2014

Open Access 01-05-2014 | Original Article

Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence

Authors: Takuzo Hashimoto, Michio Itabashi, Shinpei Ogawa, Tomoichiro Hirosawa, Yoshiko Bamba, Satoru Shimizu, Shingo Kameoka

Published in: Surgery Today | Issue 5/2014

Login to get access

Abstract

Purpose

To make a Stage II colorectal cancer (CRC) sub-classification based on clinicopathological factors.

Methods

The subjects of this study were 422 patients with Stage II CRC, who underwent curative surgery with dissection of more than 12 lymph nodes. We used the logistic regression analysis or model and Cox’s proportional hazard regression model for analysis.

Results

Preoperative carcinoembryonic antigen (CEA) level (p = 0.0057), macroscopic type (p = 0.0316), and depth of invasion (p = 0.0401) were extracted as independent risk factors for recurrence, whereas the preoperative CEA level (p = 0.0045) and depth of invasion (p = 0.0395) were extracted as independent predictors of 5-year disease-free survival. We defined depth of invasion (pT4) and the preoperative CEA level (abnormal) as risk factors for recurrence, and classified Grade A as a normal CEA level regardless of depth invasion, Grade B as depth of invasion to pT3 and an elevated CEA level, and Grade C as depth of invasion to pT4 and an elevated CEA level. There were significant differences in cumulative 5-year disease-free survival rates among each grade (Grade A vs. Grade B, p = 0.0474; Grade A vs. Grade C, p < 0.0001; Grade B vs. Grade C, p = 0.0134).

Conclusion

The sub-classification of Stage II CRC, according not only to depth of invasion but also to preoperative CEA level, is important for predicting the prognosis.
Literature
1.
go back to reference Japanese Society for Cancer of Colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Japan: Kanehara Shuppan; 2010. p. 59. Japanese Society for Cancer of Colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Japan: Kanehara Shuppan; 2010. p. 59.
2.
go back to reference Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck Arch Surg. 2002;386:575–81.CrossRef Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck Arch Surg. 2002;386:575–81.CrossRef
3.
go back to reference Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao T, Kodaira S. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelviclymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol. 2006;36:237–44.PubMedCrossRef Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao T, Kodaira S. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelviclymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol. 2006;36:237–44.PubMedCrossRef
4.
go back to reference Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer. 2007;96:1170–7.PubMedCentralPubMedCrossRef Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer. 2007;96:1170–7.PubMedCentralPubMedCrossRef
5.
go back to reference Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk Stage II colon cancer. Surg Today. 2012;42:1037–45.PubMedCrossRef Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk Stage II colon cancer. Surg Today. 2012;42:1037–45.PubMedCrossRef
6.
go back to reference Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol. 2004;22:3408–19.PubMedCrossRef Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol. 2004;22:3408–19.PubMedCrossRef
7.
go back to reference Van Cutsem EJ, Oliveira J, ESMO Guidelines Working Group. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19(Supplement 2):ii29–30.PubMed Van Cutsem EJ, Oliveira J, ESMO Guidelines Working Group. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19(Supplement 2):ii29–30.PubMed
8.
go back to reference Japanese Society for cancer of colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Tokyo: Kanehara shuppan; 2010. p. 50. Japanese Society for cancer of colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Tokyo: Kanehara shuppan; 2010. p. 50.
9.
go back to reference Japanese Society for Cancer of the Colon and Rectum edt. Japanese Classification of Colorectal Carcinoma Second English Edition. Tokyo: Kanehara & Co., Ltd. Japanese Society for Cancer of the Colon and Rectum edt. Japanese Classification of Colorectal Carcinoma Second English Edition. Tokyo: Kanehara & Co., Ltd.
10.
go back to reference Haller DG, Catalano PJ, Macdonald JS, O’Rouke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8.PubMedCrossRef Haller DG, Catalano PJ, Macdonald JS, O’Rouke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8.PubMedCrossRef
11.
go back to reference Lin CC, Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, et al. Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in single institute. Int J Colorectal Dis. 2009;24:665–76.PubMedCrossRef Lin CC, Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, et al. Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in single institute. Int J Colorectal Dis. 2009;24:665–76.PubMedCrossRef
12.
go back to reference Ishizaki T, Sumi T, Yasuda Y, Shimazu M, Katumata K, Aoki T. A study of risk factors for recurrence in stage II colorectal cancer. J Jpn Surg Assoc. 2010;71:627–33.CrossRef Ishizaki T, Sumi T, Yasuda Y, Shimazu M, Katumata K, Aoki T. A study of risk factors for recurrence in stage II colorectal cancer. J Jpn Surg Assoc. 2010;71:627–33.CrossRef
13.
go back to reference Sato H, Maeda K, Sugihara K, Mochizuki H, Teramoto T, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104:45–52.PubMedCrossRef Sato H, Maeda K, Sugihara K, Mochizuki H, Teramoto T, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104:45–52.PubMedCrossRef
14.
go back to reference Sobin LH, Wittekind Ch. TNM classification of malignant tumors, 6th edn. UICC International Union against Cancer; 2002. Sobin LH, Wittekind Ch. TNM classification of malignant tumors, 6th edn. UICC International Union against Cancer; 2002.
15.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM classification of malignant tumors, 7th edn. UICC International Union against Cancer; 2009. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM classification of malignant tumors, 7th edn. UICC International Union against Cancer; 2009.
16.
go back to reference Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–407.PubMedCrossRef Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–407.PubMedCrossRef
17.
go back to reference Schrag D, Rifas-Shiman S, Stalz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–4005.PubMedCrossRef Schrag D, Rifas-Shiman S, Stalz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–4005.PubMedCrossRef
Metadata
Title
Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence
Authors
Takuzo Hashimoto
Michio Itabashi
Shinpei Ogawa
Tomoichiro Hirosawa
Yoshiko Bamba
Satoru Shimizu
Shingo Kameoka
Publication date
01-05-2014
Publisher
Springer Japan
Published in
Surgery Today / Issue 5/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0807-y

Other articles of this Issue 5/2014

Surgery Today 5/2014 Go to the issue